Consensus AbbVie Inc. BOERSE MUENCHEN

Equities

4AB

US00287Y1091

Market Closed - BOERSE MUENCHEN Other stock markets 01:29:44 29/06/2024 am IST			5-day change	1st Jan Change
160.3 ^EUR	+1.42%		+0.24%	+14.72%

28/06	Genmab, AbbVie's Lymphoma Therapy Recommended for Approval in EU	MT
28/06	AbbVie, Genmab Receive Positive European Opinion on Marketing Authorization for Possible Lymphoma Treatment	MT

Evolution of the average Target Price on AbbVie Inc.

Price target over the last 5 years

History of analyst recommendation changes

8c16d2a4fcc1ce2.bptz8RbZ8njME3Wca1juOjpJ4mF0ODjNktACVrBtUn0.OuwSq2ervC65S0LWKDe7bkws2w09D3b08-VbJ8IgPS470DmeQ4GrP791NA~a3df59ec7ebc8a8fa782f505f6132f50

Analyst Recommendations on AbbVie Inc.

Piper Sandler Adjusts Price Target on AbbVie to $190 From $185	18/06	MT
AbbVie Says Investors Should Sit Out Tutanota Mini-Tender Offer	15/06	MT
HSBC Upgrades AbbVie to Buy From Hold, Adjusts Price Target to $185 From $161	05/06	MT
ANALYST RECOMMENDATIONS : Abbvie, Air Products, Applied Materials, KLA Corporation, UnitedHealth...	05/06
Cantor Fitzgerald Initiates AbbVie at Overweight Rating With $200 Price Target	17/05	MT
ANALYST RECOMMENDATIONS : Walmart, Netflix, Abbvie, Delta...	17/05
Daiwa Securities Adjusts Price Target on AbbVie to $171 From $190	08/05	MT
BMO Capital Cuts Price Target on AbbVie to $180 From $195, Maintains Outperform Rating	29/04	MT
Morgan Stanley Adjusts AbbVie's Price Target to $191 From $196	29/04	MT
Barclays Adjusts Price Target on AbbVie to $187 From $195	29/04	MT
Deutsche Bank Raises AbbVie's Price Target to $175 Form $170	19/04	MT
Barclays Raises AbbVie Price Target to $195 From $185, Maintains Overweight Rating	27/03	MT
Abbvie Insider Sold Shares Worth $3,716,757, According to a Recent SEC Filing	23/03	MT
Abbvie Insider Sold Shares Worth $10,539,508, According to a Recent SEC Filing	21/03	MT
ANALYST RECOMMENDATIONS : Abbvie, Align Technology; Ulta Beauty, United Airlines, Currys...	15/03
ANALYST RECOMMENDATIONS : AbbVie, Doordash, Eli Lilly, Moderna, Hiscox...	26/02
Mizuho Raises Price Target on Cerevel Therapeutics to $45 From $25 to Reflect Sale Price to AbbVie, Keeps Neutral Rating	15/02	MT
UBS Adjusts Price Target on AbbVie to $172 from $165, Maintains Neutral Rating	06/02	MT
Truist Adjusts Price Target on AbbVie to $195 From $180, Maintains Buy Rating	06/02	MT
Piper Sandler Adjusts Price Target on AbbVie to $185 From $180, Maintains Overweight Rating	05/02	MT
Morningstar Upgrades AbbVie to Hold From Sell, Increases Price Target to $168 From $137	05/02	MT
Wells Fargo Adjusts Price Target on AbbVie to $200 From $180, Maintains Overweight Rating	05/02	MT
Goldman Sachs Adjusts Price Target on AbbVie to $180 From $173, Keeps Buy Rating	05/02	MT
BMO Capital Adjusts Price Target on AbbVie to $195 From $187, Maintains Outperform Rating	05/02	MT
Barclays Adjusts Price Target on AbbVie to $185 From $175, Maintains Overweight Rating	05/02	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

171.5 USD

Average target price

183.2 USD

Spread / Average Target

+6.83%

High Price Target

207 USD

Spread / Highest target

+20.69%

Low Price Target

168 USD

Spread / Lowest Target

-2.05%

Consensus detail

Consensus revision (last 18 months)

Analysts covering AbbVie Inc.

Piper Sandler
HSBC
Cantor Fitzgerald
Daiwa Securities
BMO Capital
Mizuho Securities
Barclays
Deutsche Bank Securities
UBS
Truist Securities
Morningstar
Wells Fargo Securities
Goldman Sachs
Raymond James
William Blair & Co.
BofA Securities
Morgan Stanley
Guggenheim
Argus
Wolfe Research
Atlantic Equities
SVB Securities LLC
Credit Suisse
Societe Generale
Berenberg Bank
JPMorgan Chase
Cowen
Redburn
SVB Leerink
RBC Capital Markets

Ratings for AbbVie Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar